{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"31"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"55"}],"units":"Participants"}],"description":"Hearing loss defined by comparing hearing sensitivity at follow up evaluation relative to baseline measurements using ASHA criteria.","groups":[{"description":"Sodium thiosulfate treatment.","id":"OG000","title":"STS Arm (Sodium Thiosulfate Treatment)"},{"description":"No sodium thiosulfate treatment.","id":"OG001","title":"Observation Arm"}],"paramType":"NUMBER","populationDescription":"55 eligible patients enrolled on the observation Arm had complete audiometry data for evaluation; 49 eligible patients enrolled on the STS arm had complete data audiometry for evaluation.","reportingStatus":"POSTED","timeFrame":"4 weeks after last dose of cisplatin","title":"Incidence of Hearing Loss","type":"PRIMARY","unitOfMeasure":"Patients"}